

The E3 Ubiquitin Ligase Siah2 Contributes to Castratic Regulation of Androgen Receptor Transcriptional Activ

Cancer Cell

23, 332-346

DOI: [10.1016/j.ccr.2013.02.016](https://doi.org/10.1016/j.ccr.2013.02.016)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Deacetylase-Independent Function of HDAC3 in Transcription and Metabolism Requires Nuclear Receptor Corepressor. <i>Molecular Cell</i> , 2013, 52, 769-782.	4.5	208
2	Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation. <i>Cell</i> , 2013, 155, 1380-1395.	13.5	45
3	Ubiquitin-Proteasome Pathway and Prostate Cancer. <i>Onkologie</i> , 2013, 36, 592-596.	1.1	15
4	Investigating the Molecular Basis of Siah1 and Siah2 E3 Ubiquitin Ligase Substrate Specificity. <i>PLoS ONE</i> , 2014, 9, e106547.	1.1	17
5	Copy number alteration burden predicts prostate cancer relapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11139-11144.	3.3	299
6	Crosstalk Between Nuclear MET and SOX9/ β -Catenin Correlates with Castration-Resistant Prostate Cancer. <i>Molecular Endocrinology</i> , 2014, 28, 1629-1639.	3.7	37
7	Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. <i>Prostate</i> , 2014, 74, 421-432.	1.2	40
8	The Von Hippel-Lindau Protein Suppresses Androgen Receptor Activity. <i>Molecular Endocrinology</i> , 2014, 28, 239-248.	3.7	30
9	USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. <i>Cancer Research</i> , 2014, 74, 272-286.	0.4	98
10	Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. <i>Nature Reviews Cancer</i> , 2014, 14, 26-38.	12.8	123
11	Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1 α /OATPs signaling axis. <i>Biomaterials</i> , 2014, 35, 8175-8185.	5.7	93
12	Evaluation of protein biomarkers of prostate cancer aggressiveness. <i>BMC Cancer</i> , 2014, 14, 244.	1.1	42
13	Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 187-198.	12.8	152
14	Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants. <i>Cell Reports</i> , 2014, 6, 657-669.	2.9	217
15	Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. <i>Journal of Surgical Research</i> , 2014, 190, 203-209.	0.8	12
16	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. <i>Journal of Pathology</i> , 2015, 236, 278-289.	2.1	275
17	Implications of ubiquitin ligases in castration-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 172-176.	1.1	17
18	The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0143376.	1.1	17

#	ARTICLE	IF	CITATIONS
19	The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 405-413.	3.2	23
20	Splicing Factor Prp8 Interacts With NESAR and Regulates Androgen Receptor in Prostate Cancer Cells. <i>Molecular Endocrinology</i> , 2015, 29, 1731-1742.	3.7	15
21	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 20865-20879.	1.6	28
22	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	2.9	55
23	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. <i>International Journal of Cancer</i> , 2015, 136, E27-38.	2.3	87
24	Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. <i>Journal of Molecular Endocrinology</i> , 2015, 54, R151-R167.	1.1	34
25	Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4560-4580.	1.8	42
26	The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin. <i>Journal of Biological Chemistry</i> , 2015, 290, 21713-21723.	1.6	50
27	Dysregulation of ubiquitin ligases in cancer. <i>Drug Resistance Updates</i> , 2015, 23, 1-11.	6.5	42
28	Therapy escape mechanisms in the malignant prostate. <i>Seminars in Cancer Biology</i> , 2015, 35, 133-144.	4.3	59
29	MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer. <i>Nucleic Acids Research</i> , 2015, 43, 4893-4908.	6.5	47
30	Androgen suppresses testicular cancer cell growth <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 35224-35232.	0.8	12
31	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2289-2297.	2.0	43
32	The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer. <i>Oncotarget</i> , 2016, 7, 84201-84213.	0.8	11
33	Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines. <i>Frontiers in Genetics</i> , 2016, 7, 42.	1.1	10
34	Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 114-119.	1.2	8
35	Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer. <i>FEBS Letters</i> , 2016, 590, 908-923.	1.3	18
36	BAP18 coactivates androgen receptor action and promotes prostate cancer progression. <i>Nucleic Acids Research</i> , 2016, 44, 8112-8128.	6.5	28

#	ARTICLE	IF	CITATIONS
37	Chapter Nine - Cellular Roles of Beta-Arrestins as Substrates and Adaptors of Ubiquitination and Deubiquitination. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 141, 339-369.	0.9	18
38	Equl inhibits prostate cancer growth through degradation of androgen receptor by Sâ€phase kinaseâ€associated protein 2. <i>Cancer Science</i> , 2016, 107, 1022-1028.	1.7	31
39	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocrine-Related Cancer</i> , 2016, 23, T179-T197.	1.6	132
40	The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia. <i>Leukemia Research</i> , 2016, 42, 28-36.	0.4	12
41	Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2016, 22, 3937-3949.	3.2	24
42	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. <i>Oncogene</i> , 2017, 36, 3417-3427.	2.6	68
43	JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells. <i>BMC Cancer</i> , 2017, 17, 376.	1.1	27
44	Rationale for the development of alternative forms of androgen deprivation therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R275-R295.	1.6	17
45	The substrate binding domains of human SIAH E3 ubiquitin ligases are now crystal clear. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 3095-3105.	1.1	18
46	SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. <i>Oncogene</i> , 2017, 36, 1364-1373.	2.6	46
47	Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity. <i>Nucleic Acids Research</i> , 2017, 45, 1793-1804.	6.5	28
48	Aldoâ€Keto Reductase AKR1C1â€AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 119.	1.6	88
49	RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 529.	1.8	19
50	Identification of novel genetic etiology and key molecular pathways for seminoma via network-based studies. <i>International Journal of Oncology</i> , 2017, 51, 1280-1290.	1.4	13
51	BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. <i>Nature Communications</i> , 2018, 9, 500.	5.8	65
52	Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. <i>Oncogene</i> , 2018, 37, 1896-1910.	2.6	90
53	Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance. <i>American Journal of the Medical Sciences</i> , 2018, 355, 368-376.	0.4	20
54	DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. <i>Oncogene</i> , 2018, 37, 638-650.	2.6	46

#	ARTICLE	IF	CITATIONS
55	Ubiquitin ligases in oncogenic transformation and cancer therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 69-88.	12.8	340
56	miR-1306â€“3p targets FBXL5 to promote metastasis of hepatocellular carcinoma through suppressing snail degradation. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 820-826.	1.0	24
57	Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 86-96.	3.2	1
58	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
59	AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. <i>Theranostics</i> , 2018, 8, 676-692.	4.6	69
60	FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness. <i>Cell Death and Disease</i> , 2018, 9, 562.	2.7	38
61	Interference with the androgen receptor protein stability in therapyâ€“resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 144, 1775-1779.	2.3	22
62	Identification of diagnostic utility and molecular mechanisms of circulating miR-551b-5p in gastric cancer. <i>Pathology Research and Practice</i> , 2019, 215, 900-904.	1.0	11
63	USP39 regulates DNA damage response and chemo-radiation resistance by deubiquitinating and stabilizing CHK2. <i>Cancer Letters</i> , 2019, 449, 114-124.	3.2	37
64	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. <i>Cancer Letters</i> , 2019, 449, 145-162.	3.2	16
65	DeSUMOylase SENP7-Mediated Epithelial Signaling Triggers Intestinal Inflammation via Expansion of Gamma-Delta T Cells. <i>Cell Reports</i> , 2019, 29, 3522-3538.e7.	2.9	43
66	A molecular portrait of epithelialâ€“mesenchymal plasticity in prostate cancer associated with clinical outcome. <i>Oncogene</i> , 2019, 38, 913-934.	2.6	76
67	Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. <i>Oncogene</i> , 2019, 38, 716-730.	2.6	64
68	Activated Wnt/ β -Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. <i>Life Sciences</i> , 2020, 254, 116816.	2.0	10
69	Lipogenic effects of androgen signaling in normal and malignant prostate. <i>Asian Journal of Urology</i> , 2020, 7, 258-270.	0.5	27
70	Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP. <i>Life Sciences</i> , 2020, 242, 117159.	2.0	12
71	PEDL: extracting proteinâ€“protein associations using deep language models and distant supervision. <i>Bioinformatics</i> , 2020, 36, i490-i498.	1.8	8
72	NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer. <i>FEBS Open Bio</i> , 2020, 10, 2678-2686.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner. <i>Oncogene</i> , 2020, 39, 6677-6691.	2.6	4
74	Overview of AKR1C3: Inhibitor Achievements and Disease Insights. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11305-11329.	2.9	47
75	Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. <i>Theranostics</i> , 2020, 10, 3366-3381.	4.6	50
76	Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8515-8523.	3.3	12
77	Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1516-1528.	3.2	34
78	Emerging roles of DYRK2 in cancer. <i>Journal of Biological Chemistry</i> , 2021, 296, 100233.	1.6	34
79	Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes. <i>Nanotheranostics</i> , 2021, 5, 57-72.	2.7	1
80	Post-Translational Modifications That Drive Prostate Cancer Progression. <i>Biomolecules</i> , 2021, 11, 247.	1.8	21
81	Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 637040.	1.3	3
82	The function of BAP18 on modulation of androgen receptor action in luteinized granulosa cells from normal weight women with and without PCOS. <i>Molecular and Cellular Endocrinology</i> , 2021, 527, 111228.	1.6	5
83	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 457-472.	0.6	21
84	MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 4471-4484.	0.4	5
85	Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab150.	0.1	4
86	Amino Acid Transporters on the Guard of Cell Genome and Epigenome. <i>Cancers</i> , 2021, 13, 125.	1.7	17
87	Divergent Modulation of Proteostasis in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1233, 117-151.	0.8	13
88	The ubiquitin ligase Siah2 is revealed as an accomplice of the androgen receptor in castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 447-448.	0.8	4
89	Abstract P5-08-51: SIAH2 protein expression is inversely correlated with the ER status and outcome to tamoxifen therapy in metastatic breast cancer patients. , 2016, , .		7
90	Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less. <i>Receptors & Clinical Investigation</i> , 2014, 1, .	0.9	16

#	ARTICLE	IF	CITATIONS
91	KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 181-195.	1.6	16
92	Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2019, 26, 279-292.	1.6	8
93	PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity. <i>Oncotarget</i> , 2016, 7, 81377-81388.	0.8	14
94	Differential regulation of the androgen receptor by protein phosphatase regulatory subunits. <i>Oncotarget</i> , 2018, 9, 3922-3935.	0.8	11
95	Molecular pathways and targets in prostate cancer. <i>Oncotarget</i> , 2014, 5, 7217-7259.	0.8	84
96	SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. <i>Oncotarget</i> , 2015, 6, 771-788.	0.8	44
97	Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 29245-29254.	0.8	7
98	Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. , 2020, 3, 742-761.		13
99	A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells. <i>Life Science Alliance</i> , 2019, 2, e201800213.	1.3	12
100	The role of Siah2 in tumorigenesis and cancer therapy. <i>Gene</i> , 2022, 809, 146028.	1.0	12
103	Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4427-43.	0.5	7
104	SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. <i>American Journal of Cancer Research</i> , 2016, 6, 270-84.	1.4	5
106	Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2022, 22, 300.	1.1	2
107	m6A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 219-230.	2.3	7
108	BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer. <i>Proteomics</i> , 2022, 22, e2100172.	1.3	2
109	PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer. <i>Journal of Cancer</i> , 2022, 13, 2293-2300.	1.2	2
110	â€œThe ubiquitin ligase SIAH2 is a female-specific regulator of circadian rhythms and metabolismâ€. <i>PLoS Genetics</i> , 2022, 18, e1010305.	1.5	6
111	Fatty Acid Signaling Impacts Prostate Cancer Lineage Plasticity in an Autocrine and Paracrine Manner. <i>Cancers</i> , 2022, 14, 3449.	1.7	2

#	ARTICLE	IF	CITATIONS
112	Functional roles of E3 ubiquitin ligases in prostate cancer. <i>Journal of Molecular Medicine</i> , 2022, 100, 1125-1144.	1.7	6
113	Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. <i>Molecular Therapy</i> , 2023, 31, 78-89.	3.7	2
114	SIAH2 regulates DNA end resection and replication fork recovery by promoting CtIP ubiquitination. <i>Nucleic Acids Research</i> , 2022, 50, 10469-10486.	6.5	3
115	TGF- β 2 controls stromal telomere length through epigenetic modifications. <i>3 Biotech</i> , 2022, 12, .	1.1	1
116	The role of ubiquitination in spinal and bulbar muscular atrophy. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	7
117	Gene dosage changes in <i>KCTD13</i> result in penile and testicular anomalies via diminished androgen receptor function. <i>FASEB Journal</i> , 2022, 36, .	0.2	2
118	Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation. <i>Cancer Research Communications</i> , 2022, 2, 1693-1710.	0.7	2
119	Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. <i>Cancers</i> , 2022, 14, 6071.	1.7	7
120	CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. <i>Drug Resistance Updates</i> , 2023, 67, 100912.	6.5	4
121	SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. <i>Nucleic Acids Research</i> , 2023, 51, 2655-2670.	6.5	7
122	Analysis of the mechanism of aldo-keto reductase dependent cis-platin resistance in HepG2 cells based on transcriptomic and NADH metabolic state. <i>Biocell</i> , 2023, 47, 879-889.	0.4	0
123	A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance. <i>Science Advances</i> , 2023, 9, .	4.7	3
124	Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma. <i>Cancer Research</i> , 2023, 83, 2016-2033.	0.4	1